Evaluation of neoadjuvant chemotherapy for breast cancer using contrast-enhanced ultrasound (CE-US) imaging

Evaluation of neoadjuvant chemotherapy for breast cancer using contrast-enhanced ultrasound (CE-US) imaging - Evaluation of neoadjuvant chemotherapy for breast cancer using CE-US imaging

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000022304

Enrollment

Registered

2016-05-13

Start date

2016-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Patients who are performed neoadjuvant chemotherapy before surgery for breast cancer will be included if informed consent will be obtained. The diagnosis of breast cancer will be made using imaging findings including mammography, non-contrast enhanced ultrasound and dynamic MRI and needle biopsy. The objective of this study is one lesion which can be detected by B-mode ultrasound clearly from each patient. In patients with multiple or bilateral lesions, the lesion with largest diameter will be targeted.

Exclusion criteria

Exclusion criteria: Exclusion criteria is 1. Patients who are pregnant or breast-feeding. 2. Patients who have allergy to Sonazoid. 3. Patients who have allergy to egg. 4. Patients who have pulmonary arteriovenous shunt or right-to-left shunt. 5. Patients who have severe heart or lung disease. 6. Patients to whom contrast-enhanced CT or MRI can not be performed due to renal failure. 7. Patients who have mental disease.

Design outcomes

Primary

Measure	Time frame
To compare the quantitative parameters from contrast-enhanced ultrasound in pre-, 3 weeks, 12 weeks and 21 weeks after NAC between responders and non-responders.	—

Secondary

Measure	Time frame
1.To evaluate the possibility of non-contrast Doppler ultrasound imaging to evaluate the effectiveness of NAC. 2. To evaluate the possibility of contrast-enhanced and non-contrast Doppler ultrasound imaging to evaluate the effectiveness of NAC in lymph node metastases. 3. To evaluate the possibility of diffusion weighted imaging and dynamic contrast-enhanced imaging from MRI to evaluate the effectiveness of NAC in primary breast cancer lymph node metastases.To evaluate which parameters from contrast-enhanced ultrasound or MRI would be the best to predict the effectiveness of NAC.	—

Measure

Time frame

1.To evaluate the possibility of non-contrast Doppler ultrasound imaging to evaluate the effectiveness of NAC. 2. To evaluate the possibility of contrast-enhanced and non-contrast Doppler ultrasound imaging to evaluate the effectiveness of NAC in lymph node metastases. 3. To evaluate the possibility of diffusion weighted imaging and dynamic contrast-enhanced imaging from MRI to evaluate the effectiveness of NAC in primary breast cancer lymph node metastases.To evaluate which parameters from contrast-enhanced ultrasound or MRI would be the best to predict the effectiveness of NAC.

—

Countries

Japan

Contacts

Public ContactNaoko Mori

Tohoku Univesity Diagnostic Radiology

naokomori7127@gmail.com022-717-7312

Outcome results